跳至主要内容
临床试验/EUCTR2017-000421-13-NO
EUCTR2017-000421-13-NO进行中(未招募)1 期

ewborns with Congenital Diaphragmatic hernia: inhaled Nitric Oxide versus intravenous Sildenafil: an international randomized controlled trial - CoDiNOS trial

Erasmus MC0 个研究点目标入组 330 人开始时间: 2018年1月11日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
Erasmus MC
入组人数
330

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Diagnosis of CDH and pulmonary hypertension defined as 2 of the following 4 criteria:
  • I.PAP> 2/3 systemic pressure estimated by echocardiography
  • II.RV dilatation/septal displacement, RV dysfunction +/- LV dysfunction
  • III.Pre-post ductal SpO2 difference > 10%
  • IV.OI>20.
  • Parental informed consent
  • Children born at or after a gestational age of 34 weeks
  • Newborns who received a fetal intervention may be included
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 330
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Severe chromosomal anomaly, like trisomy 18 or trisomy 13, which may imply a decision to stop or not to start life-saving medical treatment
  • Severe cardiac anomaly, expected to need corrective surgery in the first 60 days of life (such as transposition of the great arteries, truncus arteriosus, coarctation aortae or double outlet right ventricle)
  • Renal anomalies associated with oligohydramnios
  • Severe orthopaedic and skeletal deformities, which are likely to influence thoracic, and / or lung development (such as chest wall deformities and spine anomalies)
  • Severe anomalies of the central nervous system

研究者

发起方
Erasmus MC

相似试验

Treatment of high blood pressure in the lungs in... | 临床试验